Seadler Benjamin D, Holland Hannah K, Novalija Jutta, Schena Stefano, Almassi G Hossein
Division of Cardiothoracic Surgery, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, USA.
Department of Anesthesiology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, USA.
J Cardiothorac Surg. 2025 Apr 10;20(1):183. doi: 10.1186/s13019-025-03398-7.
Pulmonary valve failure requiring replacement (PVR) is more commonly seen in children and young adults with congenital heart disease (CHD). Adults with CHD and pulmonary regurgitation have traditionally undergone PVR with bioprosthetic valves. The inspiris resilia bovine pericardial valve is an FDA-approved bioprosthesis for the aortic position with encouraging data on 7-year outcomes. Previous reports on PVR using the Inspiris valve in young patients with CHD have demonstrated early failure of the valve. We report the early failure of this device in an elder patient with idiopathic pulmonary regurgitation.
The patient is a 69-year-old male with preoperative evaluation demonstrating idiopathic pulmonary valve regurgitation with moderately depressed right ventricular ejection fraction. The patient declined receiving a porcine valve, and therefore underwent PVR using the inspiris resilia (IR) valve due to known encouraging results when implanted in the aortic position in elder patients. A 27 mm IR valve was utilized, and intraoperative transesophageal echocardiography showed no regurgitation at the time of surgery. Surveillance echocardiography at 17 months, however, already demonstrated moderate to severe pulmonary prosthetic valve regurgitation.
This report highlights an early failure of the IR valve used for PVR in an elder patient with idiopathic pulmonary regurgitation. Data on the IR valve in the pulmonic position is limited to mostly small cohorts of young patients with CHD, and immediate outcomes are nearly universally satisfactory. However, recent reports in this specific population indicate early recurrence of regurgitation in the IR cohort compared to patients managed with a commercially available porcine aortic bioprosthetic valve, when used in the pulmonic position. Our reported case suggests that utilization of IR in the pulmonic position should be approached with caution in elderly patients as well.
需要进行置换的肺动脉瓣功能衰竭(PVR)在患有先天性心脏病(CHD)的儿童和年轻人中更为常见。患有CHD和肺动脉反流的成年人传统上接受生物瓣膜置换术进行PVR。Inspiris Resilia牛心包瓣膜是一种经美国食品药品监督管理局(FDA)批准用于主动脉位置的生物假体,其7年随访结果令人鼓舞。先前关于在患有CHD的年轻患者中使用Inspiris瓣膜进行PVR的报告显示该瓣膜早期出现功能衰竭。我们报告了该装置在一名患有特发性肺动脉反流的老年患者中的早期功能衰竭情况。
该患者为一名69岁男性,术前评估显示特发性肺动脉瓣反流,右心室射血分数中度降低。患者拒绝接受猪瓣膜,因此由于已知该瓣膜植入老年患者主动脉位置时效果良好,故接受了使用Inspiris Resilia(IR)瓣膜的PVR。使用了一个27毫米的IR瓣膜,术中经食管超声心动图显示手术时无反流。然而,在17个月时的监测超声心动图已经显示出中重度人工肺动脉瓣反流。
本报告突出了IR瓣膜在一名患有特发性肺动脉反流的老年患者中用于PVR时出现的早期功能衰竭。关于IR瓣膜在肺动脉位置的数据大多限于患有CHD的年轻患者的小队列研究,且近期疗效几乎普遍令人满意。然而,最近在这一特定人群中的报告表明,与使用市售猪主动脉生物瓣膜治疗的患者相比,当IR瓣膜用于肺动脉位置时,IR队列中反流早期复发。我们报告的病例表明,在老年患者中,肺动脉位置使用IR瓣膜时也应谨慎。